Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 1/20 | 0.77 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.77 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.71 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760977 | 1.00 | PTGER1 (0.77) | PTGER1PTGER3PTGER4PTGER2 | |
| SCHEMBL12288892 | 1.00 | PTGER1 (0.77) | PTGER1PTGER3PTGER4PTGER2 | |
| SCHEMBL4995453 | 0.95 | PTGER1 (0.85) | PTGER1PTGER3PTGER4PTGER2 | |
| SCHEMBL12288895 | 0.89 | PTGER1 (0.63) | PTGER1PTGER3PTGER4PTGER2 | |
| SCHEMBL2210231 | 0.89 | PTGER1 (0.63) | PTGER1PTGER3PTGER4PTGER2 | |
| SCHEMBL4987013 | 0.88 | PTGER1 (0.75) | PTGER1PTGER3PTGER4PTGER2 | |
| SCHEMBL4993351 | 0.88 | PTGER1 (0.75) | PTGER1PTGER3PTGER4PTGER2 | |
| SCHEMBL4992003 | 0.87 | PTGER1 (1.00) | PTGER1PTGER3PTGER4 | |
| SCHEMBL4990731 | 0.87 | PTGER1 (0.74) | PTGER1PTGER3PTGER4 | |
| SCHEMBL4996181 | 0.87 | PTGER3 (0.73) | PTGER1PTGER3PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK FROSST CANADA (CA) | 2011-09-29 | — | — | US | claimed |
| US-7238710-B2 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | claimed |
| US-20040198701-A1 | EP4 receptor agonist, compositions and methods thereof | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | claimed |
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK FROSST CANADA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-RE42562-E1 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA (CA) | 2011-07-19 | — | — | US | disclosed |
| EP-1613621-B1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS | MERCK FROSST CANADA LTD (CA) | 2010-07-21 | — | — | EP | disclosed |
| US-7238710-B2 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA, LTD. (CA) | 2007-07-03 | — | — | US | disclosed |
| US-7053085-B2 | A piperidin-2-one, 1,3-oxazinan-2-one, or 1,3-thiazinan-2-one compound for treatment of glaucoma, mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts; 7-{(4S)-4-[(3R)-3-hydroxy-4-phenylbutyl]-2-oxo-1,3-oxazinan-3-yl}heptanoic acid; side effect reduction | MERCK & CO. INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1613621-A1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS | Merck Frosst Canada Ltd. (CA) | 2006-01-11 | — | — | EP | disclosed |
| US-20050227969-A1 | EP4 receptor agonist, compositions and methods thereof | MERCK CANADA INC. (CA) | 2005-10-13 | — | — | US | disclosed |
| WO-2004085430-A1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS | MERCK FROSST CANADA LTD. (CA) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085431-A1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198701-A1 | EP4 receptor agonist, compositions and methods thereof | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198701-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | PTGER1 2/4885PTGER3 3/4885PTGER4 1/4885 |
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | PTGER1 2/4885PTGER3 3/4885PTGER4 1/4885 |
| US-20050227969-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | PTGER1 2/4885PTGER3 3/4885PTGER4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.